세계의 CRISPR 시장 : 제품별(효소 및 키트, 라이브러리), 서비스별(gRNA 설계 및 세포주 개발, 스크리닝), 용도별(신약개발, 농업), 최종사용자별(제약 및 생명공학, CRO, 연구기관) 예측(-2028년)

CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028

US $ 4,950 ￦ 6,994,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,396,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,515,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,130,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 CRISPR 시장 규모는 예측 기간 동안 15.6%의 CAGR로 성장하여 2023년 34억 달러에서 2028년에는 71억 달러에 달할 것으로 예상됩니다.

CRISPR 시장의 성장을 가속하는 주요 요인은 유전자 편집 기술의 발전과 수요 증가이며, 정부 및 민간 조직의 자금 조달 및 투자 증가는 시장 성장을 가속할 것으로 예상됩니다. 그러나 윤리적, 규제적 고려사항은 시장 성장을 어느 정도 억제할 것으로 예상됩니다.

"제품 및 서비스별로는 제품 분야가 가장 큰 비중을 차지"

제품 및 서비스별로 보면, 유전자 편집 기술 분야에서 CRISPR 제품에 대한 수요 증가로 인해 제품 분야가 2023년 시장을 주도할 것으로 예상됩니다. 제품 분야 성장률 상승의 주요 요인은 전달 시스템의 발전, 유전자 편집 연구에 대한 투자 증가, 학계와 제약 기업 간의 공동 연구 증가 등을 들 수 있습니다.

"용도별로는 신약개발 분야가 가장 큰 비중을 차지"

2023년 신약개발 분야가 CRISPR 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 이 시장 부문의 성장은 유전자 편집 및 조작에서 CRISPR-Cas9이 제공하는 뛰어난 정확성과 효율성에 기인합니다. 이와 함께 개인 맞춤형 의료에 대한 수요 증가와 CRISPR 기술 분야의 연구개발 활동이 활발해짐에 따라 신약 개발 및 의약품 개발에 CRISPR을 도입하는 데 기여하고 있습니다.

"북미: 지역별 최대 시장 점유율"

CRISPR 시장에서 가장 큰 점유율을 차지하는 지역은 북미입니다. 북미의 높은 점유율은 첨단 인프라, 최첨단 연구 기관, 유전자 편집 연구를 전문으로 하는 생명공학 기업 및 CRO의 강력한 생태계 등 이 지역에서 확립된 의료 및 생명공학 산업이 큰 비중을 차지하고 있기 때문입니다. 북미에는 유전자교정 연구에 특화된 프로그램과 전문성을 갖춘 일류 학술 기관과 비상장 기업이 존재하며, 이는 CRISPR 시장 성장에 기여하고 있습니다.

"아시아태평양: CRISPR 시장에서 가장 빠르게 성장하고 있는 지역"

아시아태평양의 CRISPR 시장은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 그 배경에는 개인 맞춤형 의료에 대한 수요 증가와 시퀀싱 기술의 발전이 있습니다. 아시아태평양 CRISPR 시장의 또 다른 주요 촉진요인은 이 지역의 높은 인구와 급격한 인구 증가입니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 기술 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 공급망과 밸류체인 분석
• 생태계 분석
• Porter의 Five Forces 분석
• 규제 분석
• 가격 분석
• 특허 분석
• 주요 컨퍼런스 및 이벤트(2023년-2024년)
• 주요 이해관계자와 구입 기준

제6장 CRISPR 시장 : 제품 및 서비스별

• 서론
• 제품
  • CRISPR 효소 및 키트
  • CRISPR 라이브러리
  • 기타 제품
• 서비스
  • gRNA 합성 및 세포주 개발
  • 스크리닝 및 검증
  • 기타 서비스

제7장 CRISPR 시장 : 용도별

• 서론
• DRUG DISCOVERY & DEVELOPMENT
• 농업
• 기타 용도

제8장 CRISPR 시장 : 최종사용자별

• 서론
• 제약 기업 및 바이오테크놀러지 기업
• 학술연구기관
• 기타 최종사용자

제9장 CRISPR 시장 : 지역별

• 서론
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 구도

• 서론
• 주요 기업이 채택한 전략
• 매출 점유율 분석 : 주요 4개사
• 시장 점유율 분석(2022년)
• 기업 평가 매트릭스
• 기업 평가 매트릭스 : 스타트업/중소기업(2022년)
• 경쟁 벤치마킹
• 경쟁 시나리오와 동향

제11장 기업 개요

• 주요 기업
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • AGILENT TECHNOLOGIES, INC.
  • GENSCRIPT
  • CRISPR THERAPEUTICS AG
  • EDITAS MEDICINE
  • INTELLIA THERAPEUTICS INC.
  • BEAM THERAPEUTICS, INC.
  • CARIBOU BIOSCIENCES
  • LONZA GROUP LTD.
  • DANAHER CORPORATION
  • PERKINELMER(REVVITY, INC.)
  • HERA BIOLABS
  • ORIGENE TECHNOLOGIES, INC.
  • CELLECTA, INC.
• 기타 기업
  • MAMMOTH BIOSCIENCES INC.
  • APPLIED STEMCELL
  • NEW ENGLAND BIOLABS INC.
  • TOOLGEN INC.
  • GENECOPOEIA, INC.
  • TWIST BIOSCIENCE CORP.
  • SYNTHEGO CORPORATION
  • EGENESIS
  • INSCRIPTA, INC.
  • PRECISION BIOSCIENCES, INC.

제12장 부록

LSH

영문 목차

영문목차

The CRISPR market is projected to reach USD 7.1 billion by 2028 from USD 3.4 billion in 2023, at a CAGR of 15.6% during the forecast period. The major factors driving the growth of the CRISPR market are the advancements and increasing demand gene editing technology, and rising funding and investment of government and private organizations is expected to propel the growth of the market. However, ethical and regulatory considerations are expected to restrain market growth to a certain extent.

The CRISPR market has been segmented based on product, application, end user, and region.

"By products & services, the products segment accounted for the largest share of the CRISPR market"

Based on products & services, the CRISPR market is categorized into products, and services. The products segment dominated the market in 2023, owing to rising demand for CRISPR products in gene editing technology domain. Along with this, advancements in delivery systems, increasing investment in gene editing research and the rising number of collaborations between academic institutions and pharmaceutical companies has led to a higher growth rate for products in the CRISPR market.

"By application, drug discovery & development segment accounted for the largest share in the CRISPR market"

Based on application, the CRISPR market is segmented into drug discovery and development, agriculture, and other applications. In 2023, the drug discovery & development segment accounted for a larger share of the CRISPR market. Growth in this market segment can be attributed to exceptional precision and efficiency offered by CRISPR-Cas9 in editing and manipulating genes. Along with this, growing demand for personalized medicine, and increased research and development activities in the field of CRISPR technology are contributing to its adoption in drug discovery and development.

"North America: the largest share of the CRISPR market"

North America accounted for the largest share of the CRISPR market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in gene editing research. The presence of top academic institutions, and private companies in North America with dedicated gene editing research programs and expertise has contributed to the growth of the CRISPR market.

"Asia Pacific: The fastest-growing region in the CRISPR market."

The Asia Pacific CRISPR market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing demand of personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific CRISPR market is the region's large and rapidly increasing population.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Executives - 55%, Research Scientists- 25%, and Managers - 20%
• By Country: North America- 50%, Europe- 20%, Asia Pacific- 15%, Latin America - 10%, and Middle East Africa- 5%

Prominent Players

• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Genscript Biotech Corporation (China)
• CRISPR Therapeutics AG (Switzerland)
• Editas Medicine (US)
• Intellia Therapeutics, Inc. (US)
• Beam Therapeutics Inc. (US)
• Caribou Biosciences, Inc. (US)
• Lonza Group, Ltd. (Switzerland)
• Danaher Corporation (US)
• PerkinElmer, Inc. (US)
• Hera Biolabs (US)
• OriGene Technologies, Inc. (US)
• Cellecta, Inc. (US)
• Mammoth Biosciences, Inc. (US)
• Applied StemCell (US)
• New England Biolabs Inc. (US)
• ToolGen Inc. (South Korea)
• GeneCopoeia, Inc. (US)
• Twist Bioscience Corporation (US)
• Synthego Corporation (US)
• eGenesis (US)
• Inscripta, Inc. (US)
• Precision BioSciences, Inc. (US)

Research Coverage:

This report provides a detailed picture of the CRISPR market. It aims at estimating the size and future growth potential of the market across different segments, such as the product & services (Products(CRISPR kits & enzymes, CRISPR libraries, and other products), and services (gRNA synthesis & cell line development, CRISPR screening & validation services, and other services)), application (drug discovery & development, agriculture, and other applications), and end user (pharmaceutical and biotechnology companies, academic and research institutes, and other applications) and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CRISPR market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers:

• Analysis of key drivers (growing demand for CRISPR-based gene therapies, growing advancements and adoptions of CRISPR technology, and growing investment and funding from the government for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccine and treatment of genetic diseases), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the CRISPR market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the CRISPR market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the CRISPR market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China) among others in the CRISPR market strategies. The report also helps stakeholders understand the pulse of the gene editing market and provides them information on key market drivers, restraints, challenges and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 2 BREAKDOWN OF PRIMARIES: CRISPR MARKET
• 2.2 MARKET ESTIMATION METHODOLOGY
  • FIGURE 3 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
  • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
  • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
  • FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• 2.3 MARKET GROWTH RATE PROJECTIONS
  • FIGURE 6 CRISPR MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
  • FIGURE 7 CRISPR MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
  • 2.3.1 DATA TRIANGULATION
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
• 2.4 RESEARCH ASSUMPTIONS
• 2.5 RISK ANALYSIS
• 2.6 RECESSION IMPACT
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
  • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
  • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

• FIGURE 9 CRISPR MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 CRISPR MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 11 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

• 4.1 CRISPR MARKET OVERVIEW
  • FIGURE 12 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH
• 4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2023)
  • FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
• 4.3 CRISPR MARKET SHARE, BY END USER, 2023 VS. 2028
  • FIGURE 14 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 15 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 4 CRISPR MARKET: IMPACT ANALYSIS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for CRISPR-based gene therapies
    • 5.2.1.2 Advancements in CRISPR technology
    • 5.2.1.3 Growing government and private investments and funding for CRISPR technology
  • TABLE 5 RECENT INVESTMENTS IN CRISPR (JANUARY 2020 TO JUNE 2023)
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Technical challenges associated with CRISPR technology
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Development of new vaccines and treatments for genetic diseases
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Regulatory hurdles for CRISPR advancements
• 5.3 TECHNOLOGY ANALYSIS
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 16 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 SUPPLY AND VALUE CHAIN ANALYSIS
  • 5.5.1 CRISPR MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 17 CRISPR MARKET: SUPPLY CHAIN ANALYSIS
  • 5.5.2 CRISPR MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 18 CRISPR MARKET: VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • FIGURE 19 CRISPR MARKET: ECOSYSTEM ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 CRISPR MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF BUYERS
  • 5.7.4 BARGAINING POWER OF SUPPLIERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 REGULATORY ANALYSIS
  • 5.8.1 FDA APPROVALS
  • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.9 PRICING ANALYSIS
  • TABLE 12 AVERAGE SELLING PRICES OF PRODUCTS OFFERED BY KEY PLAYERS
  • 5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS
• 5.10 PATENT ANALYSIS
  • FIGURE 20 PATENTS GRANTED FOR CRISPR TECHNOLOGY, JANUARY 2016 TO JUNE 2023
  • TABLE 13 TOP OWNERS OF CRISPR PATENTS
• 5.11 KEY CONFERENCES AND EVENTS IN 2023-2024
  • TABLE 14 CRISPR CONFERENCES (2023-2024)
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 21 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • 5.12.2 CRISPR MARKET: BUYING CRITERIA
  • FIGURE 22 KEY BUYING CRITERIA FOR END USERS

6 CRISPR MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 15 CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 PRODUCTS
  • TABLE 16 CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 17 CRISPR PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 18 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 19 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 20 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 21 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.1 CRISPR ENZYMES AND KITS
    • 6.2.1.1 CRISPR enzymes and kits segment dominated CRISPR products market
  • TABLE 22 CRISPR ENZYMES AND KITS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 23 NORTH AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 24 EUROPE: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 26 LATIN AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.2 CRISPR LIBRARIES
    • 6.2.2.1 Increasing applications of CRISPR libraries in gene editing to drive growth
  • TABLE 27 CRISPR LIBRARIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 28 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 29 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 31 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.3 OTHER PRODUCTS
  • TABLE 32 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 33 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 34 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 36 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.3 SERVICES
  • TABLE 37 CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 38 CRISPR SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 39 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 40 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 42 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.1 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT
    • 6.3.1.1 Emerging opportunities in CRISPR gRNA synthesis and cell line development to drive growth
  • TABLE 43 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 45 EUROPE: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 46 ASIA PACIFIC: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 47 LATIN AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.2 SCREENING AND VALIDATION
    • 6.3.2.1 Rapid advancements in CRISPR technology to drive growth
  • TABLE 48 CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 50 EUROPE: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 52 LATIN AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3.3 OTHER SERVICES
  • TABLE 53 OTHER CRISPR SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 55 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 57 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 CRISPR MARKET, BY APPLICATION

• 7.1 INTRODUCTION
  • TABLE 58 CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 7.2 DRUG DISCOVERY AND DEVELOPMENT
  • 7.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH
  • TABLE 59 CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 60 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 61 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 63 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.3 AGRICULTURE
  • 7.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH
  • TABLE 64 CRISPR MARKET FOR AGRICULTURE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 66 EUROPE: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 68 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.4 OTHER APPLICATIONS
  • TABLE 69 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 70 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 71 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 73 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 CRISPR MARKET, BY END USER

• 8.1 INTRODUCTION
  • TABLE 74 CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
• 8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 8.2.1 GROWING DEMAND FOR CRISPR-BASED THERAPIES TO PROPEL GROWTH
  • TABLE 75 CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 76 NORTH AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 77 EUROPE: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 79 LATIN AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.3 ACADEMIC AND RESEARCH INSTITUTES
  • 8.3.1 GROWING FOCUS ON DEVELOPING INNOVATIVE THERAPIES TO DRIVE GROWTH
  • TABLE 80 CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 81 NORTH AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 82 EUROPE: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 84 LATIN AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION)
• 8.4 OTHER END USERS
  • TABLE 85 CRISPR MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 86 NORTH AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 87 EUROPE: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 89 LATIN AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION)

9 CRISPR MARKET, BY REGION

• 9.1 INTRODUCTION
  • TABLE 90 CRISPR MARKET, BY REGION, 2021-2028 (USD MILLION)
• 9.2 NORTH AMERICA
  • FIGURE 23 NORTH AMERICA: CRISPR MARKET SNAPSHOT
  • TABLE 91 NORTH AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 92 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 93 NORTH AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 94 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 95 NORTH AMERICA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2.1 US
    • 9.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth
  • TABLE 96 US: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 97 US: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 98 US: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 99 US: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 100 US: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2.2 CANADA
    • 9.2.2.1 Increasing demand for gene-editing technologies to boost growth
  • TABLE 101 CANADA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 102 CANADA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 103 CANADA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 104 CANADA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 105 CANADA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2.3 NORTH AMERICA: IMPACT OF RECESSION
• 9.3 EUROPE
  • TABLE 106 EUROPE: CRISPR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 107 EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 108 EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 109 EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 110 EUROPE: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 111 EUROPE: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.1 GERMANY
    • 9.3.1.1 Rapidly increasing biotechnology sector to support growth
  • TABLE 112 GERMANY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 113 GERMANY: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 114 GERMANY: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 115 GERMANY: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 116 GERMANY: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.2 UK
    • 9.3.2.1 Significant government investments in genomics research to propel growth
  • TABLE 117 UK: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 118 UK: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 119 UK: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 120 UK: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 121 UK: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.3 FRANCE
    • 9.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth
  • TABLE 122 FRANCE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 123 FRANCE: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 124 FRANCE: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 125 FRANCE: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 126 FRANCE: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.4 ITALY
    • 9.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth
  • TABLE 127 ITALY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 128 ITALY: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 129 ITALY: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 130 ITALY: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 131 ITALY: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.5 SPAIN
    • 9.3.5.1 Increasing demand for precision medicine to drive growth
  • TABLE 132 SPAIN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 133 SPAIN: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 134 SPAIN: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 135 SPAIN: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 136 SPAIN: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.6 REST OF EUROPE
  • TABLE 137 REST OF EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 138 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 139 REST OF EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 140 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 141 REST OF EUROPE: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.3.7 EUROPE: IMPACT OF RECESSION
• 9.4 ASIA PACIFIC
  • FIGURE 24 ASIA PACIFIC: CRISPR MARKET SNAPSHOT
  • TABLE 142 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 146 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.1 CHINA
    • 9.4.1.1 Increasing investments in R&D to drive growth
  • TABLE 148 CHINA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 149 CHINA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 150 CHINA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 151 CHINA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 152 CHINA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.2 JAPAN
    • 9.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth
  • TABLE 153 JAPAN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 154 JAPAN: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 155 JAPAN: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 156 JAPAN: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 157 JAPAN: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.3 INDIA
    • 9.4.3.1 Increasing prevalence of genetic disorders to support growth
  • TABLE 158 INDIA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 159 INDIA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 160 INDIA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 161 INDIA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 162 INDIA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.4 REST OF ASIA PACIFIC
  • TABLE 163 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 164 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 165 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 166 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 167 REST OF ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.4.5 ASIA PACIFIC: IMPACT OF RECESSION
• 9.5 LATIN AMERICA
  • TABLE 168 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 169 LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 170 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 172 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 173 LATIN AMERICA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.1 BRAZIL
    • 9.5.1.1 Growing adoption of genome technologies to propel growth
  • TABLE 174 BRAZIL: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 175 BRAZIL: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 176 BRAZIL: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 177 BRAZIL: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 178 BRAZIL: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.2 REST OF LATIN AMERICA
  • TABLE 179 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 180 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 181 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 182 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 183 REST OF LATIN AMERICA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.5.3 LATIN AMERICA: IMPACT OF RECESSION
• 9.6 MIDDLE EAST & AFRICA
  • TABLE 184 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 185 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 186 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 187 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 188 MIDDLE EAST & AFRICA: CRISPR MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.6.1 MIDDLE EAST & AFRICA: IMPACT OF RECESSION

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • FIGURE 25 CRISPR MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
• 10.3 REVENUE SHARE ANALYSIS (TOP 4 PLAYERS)
  • FIGURE 26 REVENUE ANALYSIS FOR TOP 4 COMPANIES (2020-2022)
• 10.4 MARKET SHARE ANALYSIS (2022)
  • FIGURE 27 CRISPR MARKET: MARKET SHARE ANALYSIS (2022)
• 10.5 COMPANY EVALUATION MATRIX
  • FIGURE 28 CRISPR MARKET: COMPANY EVALUATION MATRIX (2022)
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
• 10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES (2022)
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 STARTING BLOCKS
  • 10.6.3 RESPONSIVE COMPANIES
  • 10.6.4 DYNAMIC COMPANIES
  • FIGURE 29 CRISPR MARKET: START-UP/SME EVALUATION MATRIX (2022)
• 10.7 COMPETITIVE BENCHMARKING
  • 10.7.1 LIST OF START-UP/SME PLAYERS
  • TABLE 189 CRISPR MARKET: LIST OF START-UP/SME PLAYERS
  • 10.7.2 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • TABLE 190 CRISPR MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
• 10.8 COMPETITIVE SCENARIO AND TRENDS
  • TABLE 191 CRISPR MARKET: DEALS
  • 10.8.1 PRODUCT LAUNCHES
  • TABLE 192 CRISPR MARKET: PRODUCT LAUNCHES
  • 10.8.2 OTHER DEVELOPMENTS
  • TABLE 193 CRISPR MARKET: OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 11.1.1 THERMO FISHER SCIENTIFIC INC.
• TABLE 194 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• 11.1.2 MERCK KGAA
• TABLE 195 MERCK KGAA: COMPANY OVERVIEW
• FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2022)
• 11.1.3 AGILENT TECHNOLOGIES, INC.
• TABLE 196 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
• FIGURE 32 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022)
• 11.1.4 GENSCRIPT
• TABLE 197 GENSCRIPT: COMPANY OVERVIEW
• FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2022)
• 11.1.5 CRISPR THERAPEUTICS AG
• TABLE 198 CRISPR THERAPEUTICS AG: COMPANY OVERVIEW
• FIGURE 34 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022)
• 11.1.6 EDITAS MEDICINE
• TABLE 199 EDITAS MEDICINE: COMPANY OVERVIEW
• FIGURE 35 EDITAS MEDICINE: COMPANY SNAPSHOT (2022)
• 11.1.7 INTELLIA THERAPEUTICS INC.
• TABLE 200 INTELLIA THERAPEUTICS INC.: COMPANY OVERVIEW
• FIGURE 36 INTELLIA THERAPEUTICS INC.: COMPANY SNAPSHOT (2022)
• 11.1.8 BEAM THERAPEUTICS, INC.
• TABLE 201 BEAM THERAPEUTICS INC.: COMPANY OVERVIEW
• FIGURE 37 BEAM THERAPEUTICS INC.: COMPANY SNAPSHOT (2022)
• 11.1.9 CARIBOU BIOSCIENCES
• TABLE 202 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW
• 11.1.10 LONZA GROUP LTD.
• TABLE 203 LONZA: COMPANY OVERVIEW
• FIGURE 38 LONZA: COMPANY SNAPSHOT (2022)
• 11.1.11 DANAHER CORPORATION
• TABLE 204 DANAHER CORPORATION: COMPANY OVERVIEW
• FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
• 11.1.12 PERKINELMER (REVVITY, INC.)
• TABLE 205 PERKINELMER: COMPANY OVERVIEW
• FIGURE 40 PERKINELMER: COMPANY SNAPSHOT (2022)
• 11.1.13 HERA BIOLABS
• TABLE 206 HERA BIOLABS: COMPANY OVERVIEW
• 11.1.14 ORIGENE TECHNOLOGIES, INC.
• TABLE 207 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW
• 11.1.15 CELLECTA, INC.
• TABLE 208 CELLECTA, INC.: COMPANY OVERVIEW
• 11.2 OTHER PLAYERS
  • 11.2.1 MAMMOTH BIOSCIENCES INC.
  • 11.2.2 APPLIED STEMCELL
  • 11.2.3 NEW ENGLAND BIOLABS INC.
  • 11.2.4 TOOLGEN INC.
  • 11.2.5 GENECOPOEIA, INC.
  • 11.2.6 TWIST BIOSCIENCE CORP.
  • 11.2.7 SYNTHEGO CORPORATION
  • 11.2.8 EGENESIS
  • 11.2.9 INSCRIPTA, INC.
  • 11.2.10 PRECISION BIOSCIENCES, INC.
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료